Connect with us

Press Release

Neuralia TMS Extends Depression Treatment Access for Australian Patients

Published

2 months ago

on

Australia, 23rd Jul 2026 – Neuralia TMS, a prominent provider of Transcranial Magnetic Stimulation (TMS) therapy based in Como, Western Australia, has announced an extension of treatment access for patients across Australia seeking non-invasive, drug-free options for managing depression. The extension centres on the clinic’s combined delivery model, which pairs in-clinic TMS sessions with at-home transcranial Direct Current Stimulation (tDCS) therapy and pharmacogenetic testing, reducing the need for patients outside the Perth metropolitan area to travel for ongoing care. 

The development is relevant to patients in regional and interstate locations who have previously faced logistical barriers to accessing structured mental health treatment, and reflects broader industry attention on making evidence-based, non-drug therapies available beyond major metropolitan clinics.

TMS therapy uses magnetic fields to stimulate nerve cells in regions of the brain associated with mood regulation, and is offered as an alternative for patients who have not responded to standard approaches such as medication or talking therapies. The therapy has been the subject of more than three decades of clinical research and is listed under Medicare for treatment-resistant depression, a status that has applied since November 2021, and is delivered at Neuralia TMS’s Como facility under the oversight of its clinical team. Patients typically begin with an initial clinical assessment before a course of sessions is scheduled, with progress reviewed at regular intervals by the clinical team.

The at-home tDCS option, administered by the patient following clinical guidance, is positioned by the company as a complementary pathway for individuals who require ongoing neuromodulation support between clinic visits or who are unable to attend the Como site on a frequent basis. Patients using the at-home device are provided with instructions and remain in contact with clinical staff for monitoring purposes throughout a course of therapy. Pharmacogenetic testing is also offered to help clinicians tailor treatment plans according to a patient’s individual genetic profile, an approach intended to inform medication selection and reduce the trial-and-error process often associated with treating depression. Test results are incorporated into a patient’s broader treatment plan alongside clinical assessment, rather than used as a standalone diagnostic tool.

“Patients living in regional Western Australia and interstate have indicated that consistent travel to a clinic is not always practical,” said Dr Shanek Wick, Medical Director of Neuralia TMS. “Extending access through a combination of in-clinic and at-home therapy options allows more patients to remain engaged with a treatment plan over time.”

The updated access model applies across Neuralia TMS’s existing service lines, including TMS therapy for depression, anxiety, post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), chronic pain and Parkinson’s disease. Referral pathways remain in place through general practitioners, psychiatrists and allied health professionals, consistent with the clinic’s existing intake process. Administrative and clinical scheduling has been adjusted to accommodate patients coordinating between at-home tDCS sessions and periodic in-clinic reviews, with pharmacogenetic testing results incorporated into individual treatment planning where clinically appropriate. The clinic continues to operate from its Como premises, which house treatment rooms, consultation areas and administrative facilities supporting day-to-day operations.

Looking ahead, Dr Wick, said the company expects continued interest in flexible treatment delivery. “The combination of in-clinic and at-home therapy is expected to remain a focus as more patients seek options that fit around work, family and geographic circumstances,” said Dr Wick. “Ongoing monitoring of patient outcomes will guide how these services are adjusted over time.”

Neuralia TMS is based in Como, Western Australia, and provides TMS therapy, at-home tDCS therapy and pharmacogenetic testing for patients experiencing depression, anxiety, PTSD, OCD, chronic pain and Parkinson’s disease. The clinic operates under the oversight of a clinical team led by Dr Shanek Wick, Medical Director, and works alongside referring general practitioners, psychiatrists and allied health professionals across Western Australia. Its services are structured around non-invasive, drug-free approaches to neurological and psychiatric conditions, with treatment plans developed on an individual basis following clinical assessment. The extension of treatment access forms part of the clinic’s ongoing operations, alongside its existing in-clinic and at-home service offerings.info@neuralia.com.au Address: Unit 2A/125 Melville Parade, Marview House, Como WA 6152

For additional information about depression treatment and related industry developments, contact Neuralia TMS at Unit 2A/125 Melville Parade, Marview House, Como WA 6152. Inquiries regarding the clinic’s treatment programs, therapies and patient support services can be directed to 08 6230 3996 or by email at info@neuralia.com.au.

Media Contact

Organization: Neuralia TMS Perth (Como)

Contact Person: Dr. Shanek Wick

Website: https://www.neuraliatms.com.au/

Email: Send Email

Contact Number: +61862303996

Address:Unit 2A/125 Melville Parade

Address 2: Marview House, Como WA 6152

Country:Australia

Release id:47449

The post Neuralia TMS Extends Depression Treatment Access for Australian Patients appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Related Topics:
Continue Reading

Press Release

Carziqo Launches ER-SX Autonomous Ride-Hailing Operations in Atlanta

Published

42 minutes ago

on

September 18, 2026

By

  • The deployment introduces round-the-clock service as Carziqo expands its autonomous mobility presence across key U.S. cities

Bishopsgate, London, Sep 18, 2026, ZEX PR WIRE — Carziqo has launched operations for its ER-SX autonomous ride-hailing series in Atlanta, marking the company’s latest step in expanding its intelligent mobility network across the United States.

The ER-SX service is scheduled to operate 24 hours a day, seven days a week—from Monday through Sunday, including public holidays when service conditions permit. Through this continuous operating model, Carziqo aims to support Atlanta’s varied transportation needs, from weekday commuting and airport-related travel to weekend activity, evening journeys, and late-night mobility demand.

Atlanta is one of the most important transportation and commercial centers in the southeastern United States. The city’s expanding metropolitan population, major business districts, busy travel corridors, and diverse mobility patterns have created growing demand for transportation services that can operate beyond conventional schedules.

The introduction of the ER-SX series is intended to help address these changing travel requirements through a more flexible, technology-supported ride-hailing model.

Designed for Continuous Urban Operations

The ER-SX series has been developed for frequent urban deployment across different routes, travel distances, and operating periods. Its role within Carziqo’s fleet is not limited to serving peak commuting hours. Instead, vehicles can be assigned throughout the day and night according to local demand, route conditions, vehicle availability, and the operational requirements of specific service areas.

Carziqo’s dispatching system analyzes factors such as passenger demand, estimated travel time, vehicle location, route activity, and fleet availability when allocating vehicles. The company says this approach is designed to reduce unnecessary idle time while helping position available vehicles closer to areas where transportation demand is emerging.

In a city such as Atlanta, mobility patterns can change considerably during the day. Morning and evening commuter traffic may be followed by demand from commercial districts, entertainment areas, airports, residential communities, and late-night travelers. A 24/7 operating schedule gives the ER-SX fleet greater flexibility to respond to these shifts.

The company emphasized that round-the-clock operations do not mean every vehicle will remain on the road continuously. Individual vehicles may be temporarily rotated out of service for charging, inspection, cleaning, software checks, maintenance, or operational reassignment. The 24/7 designation refers to the availability of the overall service network, supported by coordinated fleet scheduling.

Atlanta Joins Carziqo’s Expanding Mobility Network

The Atlanta deployment forms part of Carziqo’s broader strategy to establish autonomous ride-hailing operations in cities with distinct transportation needs and strong potential for technology-enabled mobility services.

Rather than applying the same operating model in every location, the company adjusts vehicle distribution and route planning according to the characteristics of each market. Population density, commuting behavior, road conditions, passenger activity, local operating requirements, and time-based demand are among the factors considered when deploying vehicles.

For Atlanta, the ER-SX series is expected to support a combination of short-distance urban trips and longer journeys connecting residential, commercial, and transportation districts. Service coverage and vehicle allocation may be adjusted over time as the company evaluates demand patterns and operational performance.

This market-specific approach reflects a wider shift within the autonomous mobility sector. As autonomous ride-hailing technology develops, competition is increasingly moving beyond vehicle capability alone. Fleet availability, dispatching efficiency, service reliability, maintenance coordination, and the ability to respond to local demand are becoming equally important.

Technology Supported by Fleet Management

Carziqo’s Atlanta operations combine autonomous driving technology with centralized fleet-management systems. These systems help coordinate vehicle deployment, monitor operating conditions, manage service availability, and support the reassignment of vehicles when demand changes.

Operational data will also help the company evaluate how the ER-SX series performs across different periods of the week. Weekday commuting demand, Friday evening activity, weekend travel, and Sunday transportation patterns may each require different fleet configurations.

By operating Monday through Sunday, Carziqo can gather a more complete view of Atlanta’s mobility environment and refine its vehicle-allocation strategy accordingly.

The company said service availability may still vary by location and time because of maintenance requirements, road conditions, temporary restrictions, weather, charging schedules, fleet capacity, and other operational considerations. The ER-SX rollout will therefore be managed through a phased and demand-responsive deployment model.

A Step Toward More Flexible Urban Mobility

The launch comes as transportation providers increasingly explore how autonomous vehicles can complement existing mobility options in large metropolitan areas. While autonomous ride-hailing remains a developing sector, continuous service availability could become one of its most significant advantages, particularly for passengers traveling outside traditional public transportation hours.

For Atlanta, the arrival of the ER-SX series represents another addition to a transportation landscape already shaped by rapid population growth, regional commuting, airport traffic, and expanding commercial activity.

Carziqo’s decision to operate the service throughout the entire week also demonstrates the company’s focus on moving autonomous mobility from limited operating windows toward a more consistent urban service model.

As the Atlanta deployment progresses, the company is expected to continue assessing route performance, passenger demand, fleet utilization, and service reliability. These findings will guide future adjustments to operating areas and vehicle allocation.

With ER-SX vehicles now entering service in Atlanta, Carziqo is positioning the city as an important part of its growing U.S. mobility network—and as a market where autonomous ride-hailing can be tested not only during selected hours, but across the full rhythm of urban life.

The ER-SX autonomous ride-hailing service operates 24 hours a day, seven days a week, from Monday through Sunday. Actual vehicle availability and service coverage remain subject to local demand, road conditions, fleet scheduling, maintenance requirements, and applicable operational regulations.

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

RGMBS 2026 Life Sciences Innovation Forum Draws More Than USD 120 Million in Investor Interest as 23 Global Biotech Innovators Pitch in Riyadh

Published

13 hours ago

on

September 17, 2026

By

RIYADH, Saudi Arabia – The Life Sciences Innovation Forum (LSIF), the investment platform of the Riyadh Global Medical Biotechnology Summit (RGMBS 2026), brought 23 biotechnology companies from eight countries to Riyadh to pitch to investors, judges, and leaders of the Kingdom’s life sciences ecosystem.

Companies from eight countries pitched to investors across five scientific heats, with Saudi Arabia the second-largest market represented.

Dr Abdulaziz Alrifi, Director Of Partnerships, KAIMRC, stated, “We were proud to welcome leading investment firms that expressed their willingness to invest more than $USD 120 milliond in promising biotech opportunities emerging from LSIF 2026. The journey culminated with the announcement of the LSIF 2026 Grand Winner: Bilix from South Korea.”

On winning, a representative of Bilix enthused, “Winning LSIF 2026 is a great honor, however the real win is scaling our startup with the Kingdom’s research ecosystem”

Where RGMBS 2026 set out the scale of Saudi Arabia’s biotechnology ambition, LSIF put that ambition in front of the founders and investors who will shape the sector’s next decade. The United States led the cohort with eight companies, with Saudi Arabia second at four, followed by South Korea, the United Kingdom, Australia, France, Germany, and Switzerland. Several international companies presented pathways to localization, research, or clinical development in the Kingdom.

FIVE HEATS, ONE FRONTIER

Companies competed across five heats, each at the leading edge of life sciences innovation.

AI and Bio Data. Amprologix of the United Kingdom presented AI-assisted discovery of narrow-spectrum peptide antibiotics targeting drug-resistant pathogens. Pneumatica Bio of Australia combines mechanistic modelling, machine learning, and automated cell experiments to better predict human therapeutic response, while Saudi company LinusBio MENA presented precision exposomics built on hair-based biomarker profiling.

Vaccine Development and Biomanufacturing. Biotech Innovations Company of Saudi Arabia presented a recombinant-protein MERS-CoV vaccine program focused on regional biosecurity and local manufacturing. OctoCells of France presented an animal-free 3D bioscaffold platform designed to reduce the water, infrastructure, and manufacturing burden of producing biologics and cell therapies, and Cevza Therapeutics of Australia an RNA therapy platform with planned research and development localization in the Kingdom.

Cellular Therapy and Gene Editing. CellKure of the United States highlighted Phase 1 results for its multi-antigen T-cell therapy in acute myeloid leukemia. MVRIX of South Korea presented an in vivo CAR-T approach using targeted mRNA delivery, and Saudi company Medixcel a platform to bring cell and gene therapy capabilities, partnerships, and manufacturing into the Kingdom.

Bioengineering and Synthetic Biology. NanoZymeX of Switzerland presented a lipid nanoparticle platform to improve enzyme replacement therapy for lysosomal storage diseases, beginning with Pompe disease. AUREXO Therapeutics of the United States presented engineered bacterial vesicles for precision oncology, and Ingenskin Therapeutics of France an autologous skin substitute for chronic wounds, burns, and trauma.

Diagnostics and Drug Discovery. SiNON Nano Sciences of the United States presented a carbon nanoparticle platform designed to cross the blood-brain barrier. Spirea of the United Kingdom presented a dual-payload antibody-drug conjugate platform to address cancer drug resistance, and Accanito Therapeutics of the United States a clinical-stage oncology platform with a proposal for technology transfer and local manufacturing in Saudi Arabia.

Questions from judges and the audience concentrated on turning science into treatments: regulatory routes, clinical evidence, manufacturing scale-up, localization economics, and intellectual property. LSIF 2026 was sponsored by Chiyoda Corporation.

Alongside Grand Winner Bilix, four category awards were presented: the Most Scalable Biotech Startup Award to CellKure, the Outstanding Founding Team Award to Quantabia, the Breakthrough Science Award to Swaza, and the Innovation Excellence Award to Agemica.

LSIF 2026 took place as part of RGMBS 2026, held from 14 to 16 September in Riyadh. The Summit was organized and supervised by the Ministry of National Guard, represented by its Health Affairs sector, and hosted by King Abdullah International Medical Research Center (KAIMRC) and King Saud bin Abdulaziz University for Health Sciences (KSAU-HS), with the Ministry of Investment, Invest Saudi, and the Saudi Data & AI Authority (SDAIA) serving as key strategic partners.

About The Riyadh Global Medical Biotechnology Summit

The Riyadh Global Medical Biotechnology Summit is the Kingdom of Saudi Arabia’s flagship platform for medical biotechnology, convening the global scientific, investment, and policy communities in Riyadh. Organized and supervised by the Ministry of National Guard, represented by its Health Affairs sector, and hosted by KAIMRC and KSAU-HS, the Summit advances the goals of the National Biotechnology Strategy and supports the Kingdom’s emergence as a global destination for health innovation. The fourth edition took place from 14 to 16 September 2026 in Riyadh. rgmbs.org

FOR FURTHER INFORMATION

Email: PR@legends.sa

Telephone: +966 559 810 777

 

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Riyadh Global Medical Biotechnology Summit 2026 Closes as a Major Success with SAR 5.5 Billion in Agreements and announcement, Confirming Saudi Arabia’s Commitment to Lead the Future of Biotechnology

Published

13 hours ago

on

September 17, 2026

By

RIYADH, Saudi Arabia – The Riyadh Global Medical Biotechnology Summit closed today as a major success in its fourth edition and a clear statement of the scale of Saudi Arabia’s ambition in biotechnology. Over three days, more than 15,000 visitors from more than 57 countries and more than 200 speakers across more than 70 sessions saw that ambition turned into more than 40 agreements, initiatives, and announcements with a combined declared value of more than SAR 5 billion (USD 1.33 billion), up from more than USD 100 million in deal value generated at the 2024 edition. Partners came from Spain, China, Japan, Germany, the United States, South Korea, Denmark, and Malaysia to join the Kingdom’s leading universities, research centers, and manufacturers at the Sofitel Riyadh Hotel and Convention Centre, where more than 120 sponsors and exhibitors filled 6,000 square meters of event space and more than 180 strategic meetings took place.

More than 40 agreements and announcements, initiatives, and announcements worth more than SAR 5 billion (USD 1.33 billion) delivered on every pillar of the Summit, from national strategy and regulation to investment, research readiness, and talent, with participants from more than 57 countries in Riyadh.

The Summit opened on 14 September under the patronage of His Royal Highness Prince Mohammed bin Salman bin Abdulaziz Al Saud, Crown Prince and Prime Minister, and was inaugurated by His Royal Highness Prince Abdullah bin Bandar bin Abdulaziz, Minister of National Guard. His Excellency Prof. Bandar Alknawy MD , FRCPC CEO of the Ministry of National Guard Health Affairs (MNGHA) and President of King Saud bin Abdulaziz University for Health Sciences (KSAU-HS), and King Abdullah International Medical Research Center (KAIMRC) Chairman of RGMBS, addressed the opening ceremony, describing the Summit as a platform for advancing the National Biotechnology Strategy launched by His Royal Highness the Crown Prince in January 2024, at a time of rapid and far-reaching discovery in the field. Her Royal Highness Princess Dr. Maha bint Mishari bin Abdulaziz Al Saud, Chief Executive Officer of the FII Institute, addressed the opening ceremony.

Her Royal Highness highlighted the role of capital, ideas, and long-term alliances in turning scientific breakthroughs into lasting impact on humanity. She placed the human purpose of the field at the center of the Summit’s work: extending not only the length of life but its quality, so that patients gain more time, and better time, with the people they love.

FOUR PILLARS, ONE NATIONAL MISSION

RGMBS 2026 was built on four pillars under the theme Building the Foundations of Biotechnology Excellence, with each pillar explored through scientific, panel, and executive sessions.

  1. Governmental strategies and regulatory support. KAIMRC and the Ministry of Investment launched BioSync. The one stop shop for every biotech investor, consolidating the Kingdom’s entire life sciences ecosystem into a single, authoritative platform. Regulators and scientists shared the stage throughout the program, culminating in a Day Three panel on regulation as an enabling scientific tool.
  2. Investment and funding. Vaccine Industrial Company confirmed that its human vaccine manufacturing facility, a SAR 500 million investment across 42,000 square meters, is 85 percent complete and is planned to localize up to 80 percent of the Kingdom’s essential vaccine needs. Sanabil Studio by Redesign Health signed with Telepath by Tahlili on AI and digital pathology, with a potential investment of USD 3 million, and the Life Sciences Innovation Forum drew applications from more than 100 companies, nominated more than 25 for investment, and engaged five investment funds willing to invest with a combined value of more than USD 120 million.
  3. Research and development readiness. King Abdullah International Medical Research Center (KAIMRC) and Thermo Fisher Scientific announced a Center of Excellence for Genomics, Proteomics, and Biobanking. The University Hospitals Program at the Council of Universities’ Affairs signed with Novo Nordisk to build clinical trial capability, including earlier phase trials. KAIMRC also agreed research collaborations with Olink in proteomics, Tiziana Life Sciences in immunomodulation and neuroimmunology, and Japan’s Chiyoda Corporation in plant-based peptide production for cancer treatment. King Saud University and BioMe of South Korea signed to establish a microbiome joint venture, the University of Hafr Al Batin partnered with BGI Group, and Najran University launched the Najran Genomic Biobank Initiative.
  4. Building capabilities. KAIMRC signed with Rutgers University on a summer school, master’s programs, and research in artificial intelligence, and with LeapUp on training and capacity building. Princess Nourah bint Abdulrahman University and Cellenkos launched a program to develop Saudi female talent in cell and gene therapy and biomanufacturing, and SVAX and Batterjee Medical College agreed accredited biomanufacturing training with up to 350 seats per cycle. King Saud University launched four national initiatives, including an annual Saudi International Biotechnology Conference and the KSU BioHack hackathon.

THREE DAYS ON THE MAIN STAGE

  1. Day One: The program opened with the National Biotechnology Strategy and a session on global partnership with Dr. Steve Yang of WuXi AppTec, Mr. Alec Reynolds of Flagship Pioneering, and Prof. Ahmed Alaskar of KAIMRC, before turning to AI in biotechnology and multi-omics, including Prof. Jin-Soo Kim of KAIST on mitochondrial DNA editing beyond CRISPR.
  2. Day Two: Investment, immunology, and bioengineering took the stage, with Mr. Kasim Kutay of Novo Holdings on investing in AI, Prof. Keith T. Flaherty, President of the American Association for Cancer Research, on cancer immunology, Astronaut Rayyanah Barnawi on the human immune system in space, and Dr. Matthew H. Porteus of Stanford University on CRISPR-engineered cell-based drugs.
  3. Day Three: The final day focused on the biotechnology workforce and regulation, a closing keynote from Dr. Hyun-Young Park, Deputy Minister of the Korea National Institute of Health, ahead of the closing ceremony.

“RGMBS 2026 has shown the world what Saudi Arabia means when it says biotechnology is a national mission. We named this edition for foundations, and over three days those foundations were laid in full view: a vaccine plant nearing completion, a genomics center with Thermo Fisher, clinical trials with Novo Nordisk, and training for a new generation of Saudi scientists, each with a named partner and a defined scope.

“Under the direction of our leadership and the National Biotechnology Strategy, the Kingdom is committed to leading this field for decades to come. We will measure that leadership by one standard above all: the difference it makes to the lives of patients and their families.”

H.E Bandar Alknawy MD , FRCPC CEO of the Ministry of National Guard Health Affairs (MNGHA) and President of KSAU-HS and KAIMRC Chairman of RGMBS .

RGMBS 2026 was organized and supervised by the Ministry of National Guard, represented by its Health Affairs sector, and hosted by King Saud bin Abdulaziz University for Health Sciences (KSAU-HS), and King Abdullah International Medical Research Center (KAIMRC), with the Ministry of Investment, Invest Saudi, and the FII Institute serving as strategic partners. The commitments made in Riyadh advance the National Biotechnology Strategy, which targets a USD 34.6 billion contribution to non-oil GDP from biotechnology by 2040, and confirm the Kingdom’s place at the forefront of global biotechnology in the years ahead.

About The Riyadh Global Medical Biotechnology Summit

The Riyadh Global Medical Biotechnology Summit is the Kingdom of Saudi Arabia’s flagship platform for medical biotechnology, convening the global scientific, investment, and policy communities in Riyadh. Organized and supervised by the Ministry of National Guard, represented by its Health Affairs sector, and hosted by KAIMRC and KSAU-HS, the Summit advances the goals of the National Biotechnology Strategy and supports the Kingdom’s emergence as a global destination for health innovation. The fourth edition took place from 14 to 16 September 2026 in Riyadh. rgmbs.org

FOR FURTHER INFORMATION

Email: PR@legends.sa

Telephone: +966 559 810 777

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

LATEST POST

Like Us
Follow Us
Subscribe Us
Follow Us